Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
CNY 10.6
(-0.19%)
CNY 10.6
(-0.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 473.24 Million CNY | 59.06% |
| 2022 | 297.52 Million CNY | -58.24% |
| 2021 | 712.4 Million CNY | -2.05% |
| 2020 | 727.34 Million CNY | -0.66% |
| 2019 | 732.13 Million CNY | 27.5% |
| 2018 | 574.22 Million CNY | -11.37% |
| 2017 | 647.92 Million CNY | 31.88% |
| 2016 | 491.3 Million CNY | -26.48% |
| 2015 | 668.28 Million CNY | 30.25% |
| 2014 | 513.06 Million CNY | 3.83% |
| 2013 | 494.13 Million CNY | 10.75% |
| 2012 | 446.17 Million CNY | 29.37% |
| 2011 | 344.88 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 363.54 Million CNY | 430.89% |
| 2024 Q2 | 141.32 Million CNY | -61.13% |
| 2024 Q3 | -27.91 Million CNY | -119.75% |
| 2023 Q1 | 299.75 Million CNY | 294.74% |
| 2023 Q4 | -109.86 Million CNY | -164.55% |
| 2023 Q3 | 170.21 Million CNY | 50.45% |
| 2023 Q2 | 113.14 Million CNY | -62.26% |
| 2023 FY | 473.24 Million CNY | 59.06% |
| 2022 Q4 | 75.93 Million CNY | 180.94% |
| 2022 Q2 | 130.46 Million CNY | -30.93% |
| 2022 Q3 | -93.81 Million CNY | -171.91% |
| 2022 FY | 297.52 Million CNY | -58.24% |
| 2022 Q1 | 188.88 Million CNY | 18.43% |
| 2021 Q1 | 187.52 Million CNY | -3.89% |
| 2021 Q3 | -51.03 Million CNY | -131.87% |
| 2021 Q4 | 159.48 Million CNY | 412.51% |
| 2021 FY | 712.4 Million CNY | -2.05% |
| 2021 Q2 | 160.14 Million CNY | -14.6% |
| 2020 Q2 | 65.81 Million CNY | -60.42% |
| 2020 Q4 | 195.11 Million CNY | 134.06% |
| 2020 Q1 | 166.25 Million CNY | 35.39% |
| 2020 Q3 | 83.36 Million CNY | 26.67% |
| 2020 FY | 727.34 Million CNY | -0.66% |
| 2019 FY | 732.13 Million CNY | 27.5% |
| 2019 Q1 | 206.46 Million CNY | 76.22% |
| 2019 Q2 | 85.11 Million CNY | -58.77% |
| 2019 Q4 | 122.79 Million CNY | -7.66% |
| 2019 Q3 | 132.97 Million CNY | 56.23% |
| 2018 FY | 574.22 Million CNY | -11.37% |
| 2018 Q4 | 117.16 Million CNY | -27.42% |
| 2018 Q3 | 161.42 Million CNY | 48.82% |
| 2018 Q2 | 108.47 Million CNY | -42.04% |
| 2018 Q1 | 187.16 Million CNY | -8.78% |
| 2017 Q1 | 144.51 Million CNY | 69.94% |
| 2017 FY | 647.92 Million CNY | 31.88% |
| 2017 Q4 | 205.16 Million CNY | -16.66% |
| 2017 Q3 | 246.17 Million CNY | 372.84% |
| 2017 Q2 | 52.06 Million CNY | -63.97% |
| 2016 FY | 491.3 Million CNY | -26.48% |
| 2016 Q4 | 85.03 Million CNY | -54.28% |
| 2016 Q3 | 185.99 Million CNY | 48.84% |
| 2016 Q2 | 124.96 Million CNY | 31.11% |
| 2016 Q1 | 95.31 Million CNY | -71.92% |
| 2015 Q1 | 27.75 Million CNY | -87.55% |
| 2015 Q2 | 241.26 Million CNY | 769.29% |
| 2015 FY | 668.28 Million CNY | 30.25% |
| 2015 Q4 | 339.4 Million CNY | 466.93% |
| 2015 Q3 | 59.86 Million CNY | -75.19% |
| 2014 Q3 | 36.87 Million CNY | -85.15% |
| 2014 FY | 513.06 Million CNY | 3.83% |
| 2014 Q4 | 222.98 Million CNY | 504.66% |
| 2014 Q2 | 248.34 Million CNY | 5005.87% |
| 2014 Q1 | 4.86 Million CNY | 0.0% |
| 2013 FY | 494.13 Million CNY | 10.75% |
| 2012 FY | 446.17 Million CNY | 29.37% |
| 2011 FY | 344.88 Million CNY | 0.0% |